US 12,435,122 B2
Fc-epsilon CAR
Laurent H. Boissel, San Diego, CA (US); Hans G. Klingemann, San Diego, CA (US); Abhijit Dandapat, San Diego, CA (US); and Himani Chinnapen, San Diego, CA (US)
Assigned to ImmunityBio, Inc., San Diego, CA (US)
Appl. No. 17/056,385
Filed by ImmunityBio, Inc., Culver City, CA (US)
PCT Filed May 21, 2019, PCT No. PCT/US2019/033407
§ 371(c)(1), (2) Date Nov. 17, 2020,
PCT Pub. No. WO2019/226708, PCT Pub. Date Nov. 28, 2019.
Claims priority of provisional application 62/674,936, filed on May 22, 2018.
Prior Publication US 2021/0198342 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/16 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01)
CPC C07K 14/70535 (2013.01) [A61K 38/1774 (2013.01); A61K 38/2013 (2013.01); A61K 38/2086 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4203 (2025.01); A61K 40/4204 (2025.01); A61K 40/4205 (2025.01); A61K 40/421 (2025.01); A61K 40/4211 (2025.01); A61K 40/4215 (2025.01); A61K 40/4217 (2025.01); A61K 40/4221 (2025.01); A61K 40/4224 (2025.01); A61K 40/4249 (2025.01); A61K 40/4261 (2025.01); A61K 40/46 (2025.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2878 (2013.01); C07K 16/32 (2013.01); C12N 5/0646 (2013.01); A61K 2039/505 (2013.01); A61K 2239/22 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2239/49 (2023.05); A61K 2239/55 (2023.05); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01)] 8 Claims
 
1. A genetically modified NK cell, comprising:
a cytokine;
a CD16; and
a membrane bound chimeric antigen receptor (CAR) that comprises a FcεRIγ signaling domain having the amino acid sequence of SEQ ID NO:1; and
wherein the CAR is
a CD19-CAR having the amino acids 1-407 of SEQ ID NO:29,
a PD-L1-CAR encoded by a nucleic acid sequence of SEQ ID NO:42, or
a B7-H4-CAR encoded by a nucleic acid sequence of SEQ ID NO:45.